| Revision as of 23:44, 14 November 2017 editBiochemistry&Love (talk | contribs)Extended confirmed users, New page reviewers5,950 edits →Other Effects, Beta-adrenergic Receptors: +← Previous edit |
Latest revision as of 14:30, 3 January 2025 edit undoLowercase sigmabot III (talk | contribs)Bots, Template editors2,304,857 editsm Archiving 1 discussion(s) to Talk:Beta blocker/Archive 1) (bot |
| (17 intermediate revisions by 9 users not shown) |
| Line 1: |
Line 1: |
|
⚫ |
{{Talk header}} |
|
⚫ |
{{WikiProject banner shell|class=C| |
|
|
{{WikiProject Pharmacology|importance=top}} |
|
|
}} |
|
⚫ |
{{Reliable sources for medical articles}} |
|
{{User:MiszaBot/config |
|
{{User:MiszaBot/config |
|
|archiveheader = {{aan}} |
|
|archiveheader = {{aan}} |
|
|maxarchivesize = 200K |
|
|maxarchivesize = 200K |
|
|counter = 0 |
|
|counter = 1 |
|
|minthreadsleft = 0 |
|
|minthreadsleft = 0 |
|
|minthreadstoarchive = 1 |
|
|minthreadstoarchive = 1 |
| Line 8: |
Line 13: |
|
|archive = Talk:Beta blocker/Archive %(counter)d |
|
|archive = Talk:Beta blocker/Archive %(counter)d |
|
}} |
|
}} |
| ⚫ |
{{Reliable sources for medical articles}} |
|
| ⚫ |
{{talk header}} |
|
| ⚫ |
{{WikiProject Pharmacology|class=C|importance=top}} |
|
|
{{Connected contributor (paid)|User1=Cglife.trummler|U1-employer=CG Life|U1-client=Impact Journals}}. |
|
{{Connected contributor (paid)|User1=Cglife.trummler|U1-employer=CG Life|U1-client=Impact Journals}}. |
|
|
|
|
|
|
|
== Unsourced == |
|
|
|
|
|
Moved here per ] as this is almost all unsourced. Per ] please do not restore without finding reliable sources, checking the content against them, and citing the sources. |
|
|
|
|
|
;Examples |
|
|
], the first beta |
|
|
blocker]] |
|
|
|
|
|
;Nonselective agents |
|
|
Nonselective beta blockers display both β<sub>1</sub> and β<sub>2</sub> antagonism.<ref name="PharmLetter BB Table">{{cite web|title=Comparison of Oral Beta-Blockers|url=https://pharmacist.therapeuticresearch.com/Content/Segments/PRL/2012/Dec/Comparison-of-Oral-Beta-Blockers-5052|website=pharmacist.therapeuticresearch.com|publisher=Therapeutic Research Center|accessdate=30 April 2017}}</ref> |
|
|
*]<ref name="PharmLetter BB Table" /> |
|
|
*] (has additional α1-blocking activity)<ref>{{cite journal |vauthors=Rosendorff C |title=Beta-blocking agents with vasodilator activity |journal=Journal of Hypertension. Supplement |volume=11 |issue=4 |pages=S37–40 |year=1993 |pmid=8104240 |doi=10.1097/00004872-199306003-00009}}</ref> |
|
|
*]<ref>{{cite web|title=CARTEOLOL|url=https://pubchem.ncbi.nlm.nih.gov/compound/carteolol|website=pubchem.ncbi.nlm.nih.gov|publisher=U.S. National Library of Medicine|accessdate=18 October 2017|language=en}}</ref> |
|
|
*] (has additional α1-blocking activity)<ref name="PharmLetter BB Table" /> |
|
|
*] (has additional α1-blocking activity)<ref name="PharmLetter BB Table" /> |
|
|
*]<ref name="PharmLetter BB Table" /> |
|
|
*] (has intrinsic sympathomimetic activity)<ref name="oxprenolol">{{cite web|title=oxprenolol|url=https://pubchem.ncbi.nlm.nih.gov/compound/4631|website=pubchem.ncbi.nlm.nih.gov|publisher=U.S. National Library of Medicine|accessdate=18 October 2017|language=en}}</ref> |
|
|
*] (has intrinsic sympathomimetic activity)<ref name="PharmLetter BB Table" /> |
|
|
*] (has intrinsic sympathomimetic activity)<ref name="PharmLetter BB Table" /> |
|
|
*] (not considered a "typical beta-blocker")<ref name="PharmLetter BB Table" /> |
|
|
*]<ref name="PharmLetter BB Table" /> |
|
|
|
|
|
;β<sub>1</sub>-selective agents |
|
|
β<sub>1</sub>-selective beta blockers are also known as cardioselective beta blockers.<ref name="PharmLetter BB Table" /> |
|
|
*] (has intrinsic sympathomimetic activity, ISA)<ref name="PharmLetter BB Table" /> |
|
|
*]<ref name="PharmLetter BB Table" /> |
|
|
*]<ref name="PharmLetter BB Table" /> |
|
|
*]<ref name="PharmLetter BB Table" /> |
|
|
*] (has intrinsic sympathomimetic activity)<ref name="Celiprolol">{{cite web|title=Celiprolol|url=https://pubchem.ncbi.nlm.nih.gov/compound/2663|website=pubchem.ncbi.nlm.nih.gov|publisher=U.S. National Library of Medicine|accessdate=18 October 2017|language=en}}</ref> |
|
|
*]<ref name="PharmLetter BB Table" /> |
|
|
*]<ref name="PharmLetter BB Table" /> |
|
|
|
|
|
;β<sub>2</sub>-selective agents |
|
|
*]<ref>{{cite web|title=Butaxamine|url=https://pubchem.ncbi.nlm.nih.gov/compound/18026|website=pubchem.ncbi.nlm.nih.gov|publisher=U.S. National Library of Medicine|accessdate=18 October 2017|language=en}}</ref> |
|
|
*]<ref>{{cite web|title=ICI 118551 hydrochloride|url=http://www.abcam.com/ici-118551-hydrochloride-ab120808.html|website=abcam.com|publisher=Abcam plc|accessdate=18 October 2017|language=en}}</ref> |
|
|
|
|
|
;β<sub>3</sub>-selective agents |
|
|
*]<ref>{{cite web|title=SR 59230A|url=https://pubchem.ncbi.nlm.nih.gov/compound/9888075|website=pubchem.ncbi.nlm.nih.gov|publisher=U.S. National Library of Medicine|accessdate=18 October 2017|language=en}}</ref> |
|
|
|
|
|
;Comparative information |
|
|
|
|
|
;Pharmacological differences |
|
|
*Agents with intrinsic sympathomimetic action (ISA) |
|
|
**Acebutolol,<ref name="BB in HTN Meta-analyses">{{cite journal|last1=Larochelle|first1=Pierre|last2=Tobe|first2=Sheldon W.|last3=Lacourcière|first3=Yves|title=β-Blockers in Hypertension: Studies and Meta-analyses Over the Years|journal=Canadian Journal of Cardiology|date=May 2014|volume=30|issue=5|pages=S16–S22|doi=10.1016/j.cjca.2014.02.012|accessdate=18 October 2017}}</ref> pindolol,<ref name="BB in HTN Meta-analyses" /> labetalol,<ref name="BB in HTN Meta-analyses" /> mepindolol,<ref>{{cite book|last1=Mulrow|first1=edited by Detlev Ganten, Patrick J.|title=Pharmacology of Antihypertensive Therapeutics|date=1990|publisher=Springer Berlin Heidelberg|location=Berlin, Heidelberg|isbn=9783642742095|page=523|accessdate=18 October 2017}}</ref> oxprenolol<ref name="oxprenolol" />, celiprolol<ref name="Celiprolol" />, penbutolol<ref name="PharmLetter BB Table" /> |
|
|
*Agents organized by lipid solubility (lipophilicity)<ref>{{cite journal|last1=Zipursky|first1=Jonathan S.|last2=Macdonald|first2=Erin M.|last3=Luo|first3=Jin|last4=Gomes|first4=Tara|last5=Mamdani|first5=Muhammad M.|last6=Paterson|first6=J. Michael|last7=Juurlink|first7=David N.|title=Lipophilic β-Blockers and Suicide in the Elderly|journal=Journal of Clinical Psychopharmacology|date=June 2017|volume=37|issue=3|pages=381–384|doi=10.1097/JCP.0000000000000695|url=https://insights.ovid.com/pubmed?pmid=28338548|accessdate=18 October 2017}}</ref> |
|
|
**High lipophilicity: propranolol, labetalol |
|
|
**Intermediate lipophilicity: metoprolol, bisoprolol, carvedilol, acebutolol, timolol, pindolol |
|
|
**Low lipophilicity (also known as hydrophilic beta-blockers): atenolol, nadolol, and sotalol |
|
|
*Agents with ]<ref name="Aronson">{{cite journal|last1=Aronson|first1=Jeffrey K|title=Changing beta-blockers in heart failure: when is a class not a class?|journal=British Journal of General Practice|date=1 June 2008|volume=58|issue=551|pages=387–389|doi=10.3399/bjgp08X299317|accessdate=18 October 2017}}</ref> |
|
|
**Carvedilol, propranolol > oxprenolol > labetalol, metoprolol, timolol |
|
|
|
|
|
;Indication differences |
|
|
*Agents specifically labeled for cardiac arrhythmia |
|
|
**],<ref name="Esmolol package insert">{{cite web|title=BREVIBLOC (esmolol hydrochloride)|publisher=Baxter Healthcare Corporation|accessdate=18 October 2017}}</ref> ],<ref>{{cite web|title=BETAPACE AF (sotalol HCl)|publisher=Bayer HealthCare Pharmaceuticals Inc.|accessdate=18 October 2017}}</ref> ] (Japan)<ref>{{cite web|title=Announcement of Approval of Additional Indications for Onoact® 50 for Injection, Short-Acting Selective ß1 Blocker|url=http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=103244|website=www.evaluategroup.com|publisher=Evaluate Ltd|accessdate=18 October 2017}}</ref> |
|
|
*Agents specifically labeled for congestive heart failure<ref name="PharmLetter BB Table" /> |
|
|
**], ] |
|
|
*Agents specifically labeled for glaucoma |
|
|
**],<ref name="Aronson" /> ],<ref name="Aronson" /> ],<ref name="Aronson" /> ],<ref name="Aronson" /> ]<ref>{{cite web|title=DailyMed - METIPRANOLOL- metipranolol solution/ drops|url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=699ce415-0798-4244-b5ec-bcdb383b50b3|website=dailymed.nlm.nih.gov|publisher=NIH|accessdate=18 October 2017}}</ref> |
|
|
*Agents specifically labeled for myocardial infarction<ref name="PharmLetter BB Table" /> |
|
|
**], ] (immediate release), ] (immediate release), ], ] (after left ventricular dysfunction) |
|
|
*Agents specifically labeled for migraine prophylaxis<ref name="PL Chart Migraine">{{cite web|title=Drugs to Prevent Migraine in Adults|url=https://pharmacist.therapeuticresearch.com/Content/Segments/PRL/2012/Jul/Drugs-to-Prevent-Migraine-in-Adults-4513|website=pharmacist.therapeuticresearch.com|publisher=Therapeutic Research Center|accessdate=30 April 2017}}</ref> |
|
|
**], ] |
|
|
|
|
|
] is the only agent indicated for control of tremor, portal hypertension, and esophageal variceal bleeding, and used in conjunction with α-blocker therapy in ].<ref name="Rossi"/> |
|
|
|
|
|
{{reflist-talk}} |
|
|
{{reply to|Jytdog}} I've finished the necessary citing and have moved the material over. Thank you for bringing this important issue to our attention.―] 04:09, 18 October 2017 (UTC) |
|
|
::Thanks for taking care of that! So much work! ] (]) 05:17, 18 October 2017 (UTC)r |
|
|
|
|
|
== Expand on Other Effects == |
|
|
|
|
|
The "Other effects" section mentions beta-adrenergic mediated inhibition of melatonin secretion. It might be useful to discuss the differences in melatonin secretion inhibition between beta blockers. ―] 04:11, 18 October 2017 (UTC) |
|
|
|
|
|
== Other Effects, Beta-adrenergic Receptors == |
|
|
|
|
|
Proposed addition: "Because beta-adrenergic receptors are expressed across a diverse group of cancers, researchers are exploring ways to identify tumor types that would be responsive to beta blockers." Citation: |
|
|
|
|
|
This section on non-cardiological indications should be supported, although this citation is admittedly primary research. Do you think this adds reliable, valuable information to this article?] (]) 23:02, 14 November 2017 (UTC) |
|
|
:I couldn't view the citation. Can you give a DOI? |
|
|
:I found a review article on the subject , but I haven't read it. See: Coelho, M., Soares-Silva, C., Brandão, D. et al. ''J Cancer Res Clin Oncol''. 2017;143:275.―] 23:43, 14 November 2017 (UTC) |
|
.
